Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus GADOTERIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus GADOTERIDOL.
ANGIOVIST 282 vs GADOTERIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Gadoteridol is a paramagnetic gadolinium-based contrast agent that increases signal intensity in T1-weighted magnetic resonance imaging by shortening the T1 relaxation time of protons in water molecules. It distributes in the extracellular fluid compartment and does not cross the intact blood-brain barrier, thus enhancing imaging in areas of disrupted barrier or abnormal vascularity.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
0.2 mL/kg (0.1 mmol/kg) IV bolus, max 20 mL per dose; additional doses up to 0.4 mL/kg may be given within 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 10-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Renal: >95% unchanged via glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Contrast Agent
Contrast Agent